Formulary
Lanadelumab: Indications, Dosing, Side Effects and Interactions
Lanadelumab is a humanised monoclonal antibody which inhibits plasma kallikrein activity, thereby limiting the production of bradykinin, a potent vasodilator...
MedNext Academy | 3 min read
Lanadelumab: Indications, Dosing, Side Effects and Interactions
Lanadelumab is a humanised monoclonal antibody which inhibits plasma kallikrein activity, thereby limiting the production of bradykinin, a potent vasodilator...
Drug action
Lanadelumab is a humanised monoclonal antibody which inhibits plasma kallikrein activity, thereby limiting the production of bradykinin, a potent vasodilator associated with angioedema attacks in patients with hereditary angioedema.
Indications and dose
**Prevention of recurrent attacks of hereditary angioedema (initiated under specialist supervision)**
- **Adult** (By Subcutaneous Injection): 300 mg every 2 weeks, reduced to 300 mg every 4 weeks, in those stable and attack free-consult product literature.
**Prevention of recurrent attacks of hereditary angioedema (initiated under specialist supervision) for lanadelumab**
- **Child 12-17 years** (By subcutaneous injection): 300 mg every 2 weeks, reduced to 300 mg every 4 weeks, in those stable and attack free-consult product literature.
Contraindications
Not a treatment for acute attacks of angioedema-initiate individualised treatment for breakthrough attacks
Side effects
Common or very common Dizziness; hypersensitivity; myalgia; oral disorders; skin reactions
Interactions
**Other interactions (2):**
- Based on the characteristics of lanadelumab, no pharmacokinetic interactions with co-administered medicinal products is expected.
- As expected, concomitant use of the rescue medication C1 esterase inhibitor results in an additive effect on lanadelumab-cHMWK response based on the mechanism of action of lanadelumab and C1...
Pregnancy
Manufacturer advises preferable to avoid-limited or no information available; animal studies do not indicate toxicity.
Breast feeding
Manufacturer advises avoid during first few days after birth-possible risk from transfer of antibodies to infant. After this time, use during breast-feeding only if clinically needed.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Lanadelumab in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

